Treatment for Genitourinary Cancers

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
UC Davis Medical Center, Sacramento, CA
Genitourinary Cancers+1 More
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a new imaging method may help doctors determine if a treatment is working sooner.

See full description

Eligible Conditions

  • Genitourinary Cancers

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 2 primary outcomes, 1 secondary outcome, and 1 other outcome in patients with Genitourinary Cancers. Measurement will happen over the course of Two weeks.

One year after treatment
Inclusion of Minority Cohort
Two months
Correlation with tumor anatomical response
Two weeks
Changes in blood flow
Changes in blood volume

Trial Safety

Safety Estimate

1 of 3

Trial Design

0 Treatment Group

This trial requires 20 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: one year after treatment
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly one year after treatment for reporting.

Closest Location

UC Davis Medical Center - Sacramento, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Patients with pathologically confirmed GUC. For those patients whose primary kidney cancer is removed, they must have index metastatic cancer lesion(s) within the PET field of view for 18F-FDG parametric PET/CT analysis to determine response.
Patients are scheduled for targeted cancer therapy, including sunitinib, pazopanib, cabozantinib, everolimus, and others.
Ability to understand and willingness to sign an informed consent form.
You are able to attend the study visit schedule and other protocol requirements. show original
You are between 21 and 49. show original
Life expectancy ≥ 6months.
Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first drug administration.
Male and female subjects who agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices [IUDs], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 90 days after the last dose of drug.
You are a member of a Federally recognized racial/ethnic minority population. show original

Patient Q&A Section

What causes urogenital neoplasms?

"In this cohort of patients with germ cell tumors, a significant proportion of the cancers were attributable to factors other than the genitostructure (primary cancer site), indicating the need to develop the proper treatment for local cancers. For cancers arising in the testis and ovary, the primary (genitostructural) site should be considered the standard treatment, not surgery." - Anonymous Online Contributor

Unverified Answer

What is urogenital neoplasms?

"Urogenital neoplasms is a heterogenous disease involving both benign and malignant tumors. The prevalence of cancer is high, whereas malignancy is rare in females younger than 40 years of age. The most frequent site for cancers is the urinary tract. Histologically, most cancers are transitional cell carcinomas of the urinary tract. Urinary tract cancer can be divided into bladder, rectum and prostate cancer. As most common of cancers is transitional cell carcinoma of the bladder, more information on the biology and prevention must be investigated." - Anonymous Online Contributor

Unverified Answer

How many people get urogenital neoplasms a year in the United States?

"Urogenital neoplasms are common. [Progression rates are less than previously reported] The incidence of urogenital neoplasms increases with age and has a female preponderance. [Falling incidence rates will make cancer control initiatives more attractive and accessible to a larger patient population." - Anonymous Online Contributor

Unverified Answer

Can urogenital neoplasms be cured?

"Neoplasms of the upper urinary tract cannot be cured. However, modern chemotherapy, immunotherapy, radiological techniques and urologic manipulation can reduce the effects on quality of life, but never cure the disease. It seems that complete remission can only be achieved in patients with inoperable or metastatic disease." - Anonymous Online Contributor

Unverified Answer

What are common treatments for urogenital neoplasms?

"Most urogenital cancers are treated with surgery, chemotherapy, radiation therapy, hormonal therapy, or a combination of these. More aggressive cancers frequently involve metastatic dissemination, which may require local or systemic therapies." - Anonymous Online Contributor

Unverified Answer

What are the signs of urogenital neoplasms?

"Urogenital neoplasms may present with urinary tract symptoms, vaginal discharge, gynecological complaints or pelvic abnormalities. In particular, urinary tract symptoms in women or gynecological complaints in men may suggest a urogenital neoplasm. In contrast, symptoms suggestive of urinary tract infection and an inability to urinate are more strongly suggestive of urogenital malignancy than other types of symptoms." - Anonymous Online Contributor

Unverified Answer

Is treatment safe for people?

"Radiation exposure appears to be the only predictor of grade toxicity following RT for anal cancer and urethral cancer. Most grade 3 or 4 pelvic-femoral-tibia or pelvic-femoral-pelvis toxicity is caused by high doses or poor organ positioning following RT. In particular, grade 4 or higher toxicity is uncommon following treatment of anal cancer and urethral cancer. Radiation doses are consistently associated with pelvic-femoral-pelvis or pelvic-femoral-tibia and pelvic-femoral-femoral toxicity following RT. Radiation doses ≤50 Gy are typically sufficient to control cancer, with less stringent treatment being safer than more aggressive treatment." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of urogenital neoplasms?

"Recent findings of this study suggest that urogenital epithelial neoplasms were caused by diverse factors, although the vast majority of cases were not associated with hereditary tumors, which could be attributable to lifestyle and environmental factors. When a primary neoplasm is present, it may influence prognosis and a more accurate classification in terms of risk of metastasis and therapeutic approach are necessary." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating urogenital neoplasms?

"As more trials are conducted on treatment for urogenital neoplasms, it is expected that treatment for these tumors will continue to evolve. Clinical trials can be an important resource for treating urogenital neoplasms because of the high level of patients seeking treatment for different urogenital neoplasms." - Anonymous Online Contributor

Unverified Answer

Does urogenital neoplasms run in families?

"The data support the hypothesis that UOGN occurrence may be associated with other familial cancers of the endocrine-metabolism apparatus. Furthermore, the results suggest that hereditary malignancies are associated with a significant increment in the risk of UOGN. Further studies with a larger sample size and longer follow-up periods are needed to confirm these results." - Anonymous Online Contributor

Unverified Answer

How does treatment work?

"We believe that this guideline is a valuable resource for pediatric urologist. It describes the approach to children with various urogenital masses. It provides helpful and comprehensive information. This guideline also contains a comprehensive list of treatment options that is easy to access for any pediatric urologist or treating physician." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in treatment for therapeutic use?

"There has been many advances in the surgical field. The main goal of surgery is to take the cancer out while remaining as close to normal tissue as possible. There is still much to discover as well regarding surgery's role in oncology. The future may see new and improved treatment based on improved imaging techniques and improved instrumentation." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Genitourinary Cancers by sharing your contact details with the study coordinator.